Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$74.80
+0.8%
$74.41
$55.02
$98.40
$3.55B1.13532,123 shs767,615 shs
Envista Holdings Co. stock logo
NVST
Envista
$19.00
-4.1%
$20.66
$18.09
$36.74
$3.27B1.351.98 million shs2.24 million shs
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$70.00
-1.8%
$71.12
$55.96
$75.31
$3.48B0.53198,460 shs223,436 shs
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
$28.29
-0.3%
$32.13
$26.27
$41.65
$5.87B12.67 million shs4.51 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
0.00%+4.31%+3.64%-19.41%+3.95%
Envista Holdings Co. stock logo
NVST
Envista
-0.05%-6.82%-7.23%-20.03%-49.52%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
-0.04%-0.67%+0.33%+13.12%+14.29%
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
0.00%-7.46%-11.37%-17.26%-30.11%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.4781 of 5 stars
4.50.00.04.52.04.20.6
Envista Holdings Co. stock logo
NVST
Envista
4.5307 of 5 stars
4.04.00.03.82.20.01.9
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
3.8447 of 5 stars
3.32.00.03.52.42.50.6
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
4.8594 of 5 stars
4.32.03.33.81.81.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.92
Moderate Buy$122.0063.10% Upside
Envista Holdings Co. stock logo
NVST
Envista
1.92
Reduce$25.8636.12% Upside
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
2.50
Moderate Buy$110.0057.14% Upside
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
2.64
Moderate Buy$35.8926.86% Upside

Current Analyst Ratings

Latest NVST, XRAY, AXSM, and PBH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/3/2024
Envista Holdings Co. stock logo
NVST
Envista
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$20.00 ➝ $17.50
5/3/2024
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$40.00 ➝ $35.00
5/3/2024
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$41.00 ➝ $38.00
5/3/2024
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$35.00 ➝ $32.00
5/3/2024
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $36.00
5/3/2024
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$35.00 ➝ $33.00
5/2/2024
Envista Holdings Co. stock logo
NVST
Envista
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$29.00 ➝ $23.00
5/2/2024
Envista Holdings Co. stock logo
NVST
Envista
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
5/2/2024
Envista Holdings Co. stock logo
NVST
Envista
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$22.00 ➝ $19.00
4/29/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$90.00 ➝ $115.00
4/26/2024
Envista Holdings Co. stock logo
NVST
Envista
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$33.00 ➝ $21.00
(Data available from 5/5/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$270.60M13.13N/AN/A$4.04 per share18.51
Envista Holdings Co. stock logo
NVST
Envista
$2.57B1.27$2.55 per share7.46$24.09 per share0.79
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.13B3.08$5.01 per share13.97$29.12 per share2.40
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
$3.97B1.48$4.83 per share5.86$15.71 per share1.80

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$239.24M-$5.20N/A110.00N/A-88.41%-70.67%-27.47%5/6/2024 (Confirmed)
Envista Holdings Co. stock logo
NVST
Envista
-$100.20M-$0.72N/A13.383.68-4.70%5.84%3.74%8/7/2024 (Estimated)
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
-$82.31M-$1.64N/A15.181.90-7.11%14.09%6.39%5/14/2024 (Confirmed)
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
-$132M-$0.44N/A12.041.15-2.41%11.54%5.36%8/7/2024 (Estimated)

Latest NVST, XRAY, AXSM, and PBH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2024N/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.14N/A-$1.14N/AN/AN/A  
5/6/2024N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$1.22N/A+$1.22N/AN/AN/A  
5/2/2024Q1 24
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
$0.42$0.42N/A$0.75$969.45 million$953.00 million      
5/1/2024Q1 2024
Envista Holdings Co. stock logo
NVST
Envista
$0.31$0.26-$0.05$0.38$634.85 million$623.60 million    
2/29/2024Q4 23
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
$0.43$0.44+$0.01$0.56$972.61 million$1.01 billion    
2/20/2024Q4 2023
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$1.21-$0.73+$0.48$0.62$70.38 million$71.53 million
2/8/202412/31/2023
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.04$1.06+$0.02$1.06$280.25 million$282.74 million      
2/7/2024Q4 2023
Envista Holdings Co. stock logo
NVST
Envista
$0.33$0.29-$0.04$1.85$638.37 million$645.60 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Envista Holdings Co. stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
N/AN/AN/AN/AN/A
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
$0.642.26%+11.87%N/A 13 Years

Latest NVST, XRAY, AXSM, and PBH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/27/2024
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
quarterly$0.161.92%3/27/20243/29/20244/12/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
0.93
3.63
3.52
Envista Holdings Co. stock logo
NVST
Envista
0.34
2.27
1.90
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
0.75
3.09
1.92
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
0.54
1.43
0.95

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Envista Holdings Co. stock logo
NVST
Envista
N/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
99.95%
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
95.70%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
24.50%
Envista Holdings Co. stock logo
NVST
Envista
1.30%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
1.60%
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
0.52%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
54547.49 million35.86 millionOptionable
Envista Holdings Co. stock logo
NVST
Envista
12,800171.86 million169.62 millionOptionable
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
56049.65 million48.86 millionOptionable
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
15,000207.36 million206.29 millionOptionable

NVST, XRAY, AXSM, and PBH Headlines

SourceHeadline
DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Cut to $38.00DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Cut to $38.00
americanbankingnews.com - May 5 at 6:18 AM
Needham & Company LLC Lowers DENTSPLY SIRONA (NASDAQ:XRAY) Price Target to $36.00Needham & Company LLC Lowers DENTSPLY SIRONA (NASDAQ:XRAY) Price Target to $36.00
americanbankingnews.com - May 5 at 6:18 AM
DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Cut to $35.00DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Cut to $35.00
americanbankingnews.com - May 5 at 6:18 AM
DENTSPLY SIRONA (NASDAQ:XRAY) Rating Reiterated by Piper SandlerDENTSPLY SIRONA (NASDAQ:XRAY) Rating Reiterated by Piper Sandler
americanbankingnews.com - May 5 at 5:44 AM
DENTSPLY SIRONA (NASDAQ:XRAY) PT Lowered to $33.00DENTSPLY SIRONA (NASDAQ:XRAY) PT Lowered to $33.00
americanbankingnews.com - May 5 at 3:54 AM
StockNews.com Downgrades DENTSPLY SIRONA (NASDAQ:XRAY) to HoldStockNews.com Downgrades DENTSPLY SIRONA (NASDAQ:XRAY) to Hold
americanbankingnews.com - May 5 at 3:54 AM
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives Average Rating of "Moderate Buy" from AnalystsDENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives Average Rating of "Moderate Buy" from Analysts
americanbankingnews.com - May 5 at 1:28 AM
DENTSPLY SIRONA (NASDAQ:XRAY) Stock Rating Lowered by StockNews.comDENTSPLY SIRONA (NASDAQ:XRAY) Stock Rating Lowered by StockNews.com
marketbeat.com - May 4 at 12:28 AM
DENTSPLY SIRONA (NASDAQ:XRAY) Releases FY 2024 Earnings GuidanceDENTSPLY SIRONA (NASDAQ:XRAY) Releases FY 2024 Earnings Guidance
marketbeat.com - May 3 at 8:18 PM
DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Lowered to $35.00 at Evercore ISIDENTSPLY SIRONA (NASDAQ:XRAY) Price Target Lowered to $35.00 at Evercore ISI
marketbeat.com - May 3 at 8:08 PM
Dentsply Sirona Inc (XRAY) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...Dentsply Sirona Inc (XRAY) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...
finance.yahoo.com - May 3 at 8:27 AM
Dentsply: Q1 Earnings SnapshotDentsply: Q1 Earnings Snapshot
timesunion.com - May 2 at 7:04 PM
Dentsply, Execs Must Face Investors’ Securities Fraud Class SuitDentsply, Execs Must Face Investors’ Securities Fraud Class Suit
news.bloomberglaw.com - May 2 at 7:04 PM
DENTSPLY SIRONA (NASDAQ:XRAY)  Shares Down 5.8% DENTSPLY SIRONA (NASDAQ:XRAY) Shares Down 5.8%
marketbeat.com - May 2 at 6:56 PM
DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/YDENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y
zacks.com - May 2 at 2:06 PM
Dentsply Sirona Falls Over 4% Following Q1 Results - Read WhyDentsply Sirona Falls Over 4% Following Q1 Results - Read Why
msn.com - May 2 at 2:03 PM
Heres What Key Metrics Tell Us About Dentsply (XRAY) Q1 EarningsHere's What Key Metrics Tell Us About Dentsply (XRAY) Q1 Earnings
zacks.com - May 2 at 12:31 PM
DENTSPLY SIRONA (NASDAQ:XRAY) Issues FY24 Earnings GuidanceDENTSPLY SIRONA (NASDAQ:XRAY) Issues FY24 Earnings Guidance
marketbeat.com - May 2 at 10:54 AM
DENTSPLY SIRONA (NASDAQ:XRAY) Announces Quarterly  Earnings Results, Hits EstimatesDENTSPLY SIRONA (NASDAQ:XRAY) Announces Quarterly Earnings Results, Hits Estimates
marketbeat.com - May 2 at 10:39 AM
Dentsply Sirona Inc (XRAY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Sales DeclineDentsply Sirona Inc (XRAY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Sales Decline
finance.yahoo.com - May 2 at 9:01 AM
Dentsply International (XRAY) Meets Q1 Earnings EstimatesDentsply International (XRAY) Meets Q1 Earnings Estimates
zacks.com - May 2 at 8:11 AM
Dentsply Sirona Reports First Quarter 2024 ResultsDentsply Sirona Reports First Quarter 2024 Results
globenewswire.com - May 2 at 6:00 AM
Aesthetic Devices Market Report 2024 Industry Trends, Plant Setup, Machinery, Cost and RevenueAesthetic Devices Market Report 2024 Industry Trends, Plant Setup, Machinery, Cost and Revenue
taiwannews.com.tw - May 1 at 10:06 AM
Russell Investments Group Ltd. Has $32.04 Million Position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY)Russell Investments Group Ltd. Has $32.04 Million Position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
marketbeat.com - May 1 at 6:21 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Axsome Therapeutics logo

Axsome Therapeutics

NASDAQ:AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Envista logo

Envista

NYSE:NVST
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Prestige Consumer Healthcare logo

Prestige Consumer Healthcare

NYSE:PBH
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
DENTSPLY SIRONA logo

DENTSPLY SIRONA

NASDAQ:XRAY
DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform. It also provides endodontic products consisting of motorized endodontic handpieces, files, sealers, irrigation needles, and other tools that support root canal procedures; restorative products, including dental ceramics, crowns, and veneers; and preventative products, such as curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, and impression materials. In addition, the company offers SureSmile and Byte aligner solutions; VPro/HyperByte, a high-frequency vibration technology device; SureSmile Simulator, which creates a 3D visualization of a patient's outcome; and Byte Plus for treatment planning. Further, it provides dental implants, digital dentures, crown and bridge porcelain products, bone regenerative and restorative solutions, treatment planning software, and educational programs; dental prosthetics; urology catheters; and other health-related consumables. The company serves professional dental and consumable medical device markets through third-party distributors. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina